Anish Bali
Royal Derby Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anish Bali.
Clinical & Translational Oncology | 2011
Viren Asher; Joanne Lee; Anni Innamaa; Anish Bali
IntroductionOvarian cancer is associated with high mortality due to presentation at advanced stage and high recurrence following treatment with chemotherapy. Most of the prognostic variables in ovarian cancer, including stage and residual disease, are amenable for assessment only after surgery. Currently there are no established preoperative markers including, CA-125, that can predict overall survival in patients with ovarian cancer. The aim of our study was to evaluate the prognostic significance of the preoperative haematological markers platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) in patients with ovarian cancer.MethodPreoperative PLR and NLR were evaluated in 235 patients undergoing surgery for ovarian cancer. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods.ResultsHigh preoperative PLR (p<0.001) and NLR (p=0.001) were significantly associated with poor survival using univariate Cox survival analysis. The median overall survival in patients with a PLR of <300 was 37.4 months (95%CI 26.1–48.7) and 14.5 months (95%CI 11.7–17.2) in those with a PLR of >300. PLR (p=0.03) but not NLR (p=0.575) retained its significance as a prognostic marker on multivariate Cox’s regression analysis, along with stage (p<0.001) and residual disease (p=0.015).ConclusionWe have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer.
World Journal of Surgical Oncology | 2010
Viren Asher; Heidi M. Sowter; Robert Shaw; Anish Bali; Raheela Khan
Voltage gated potassium channels have been extensively studied in relation to cancer. In this review, we will focus on the role of two potassium channels, Ether à-go-go (Eag), Human ether à-go-go related gene (HERG), in cancer and their potential therapeutic utility in the treatment of cancer. Eag and HERG are expressed in cancers of various organs and have been implicated in cell cycle progression and proliferation of cancer cells. Inhibition of these channels has been shown to reduce proliferation both in vitro and vivo studies identifying potassium channel modulators as putative inhibitors of tumour progression. Eag channels in view of their restricted expression in normal tissue may emerge as novel tumour biomarkers.
Diagnostic Pathology | 2010
Viren Asher; Raheela Khan; Averil Y. Warren; Robert Shaw; Gerhard van Schalkwyk; Anish Bali; Heidi M. Sowter
BackgroundOvarian cancer is the second most common cancer of the female genital tract in the United Kingdom (UK), accounting for 6% of female deaths due to cancer. This cancer is associated with poor survival and there is a need for new treatments in addition to existing chemotherapy to improve survival. Potassium (K+) channels have been shown to be overexpressed in various cancers where they appear to play a role in cell proliferation and progression.ObjectivesTo determine the expression of the potassium channels Eag and HERG in ovarian cancer tissue and to assess their role in cell proliferation.MethodsThe expression of Eag and HERG potassium channels was examined in an ovarian cancer tissue microarray. Their role in cell proliferation was investigated by blocking voltage-gated potassium channels in an ovarian cancer cell line (SK-OV-3).ResultsWe show for the first time that high expression of Eag channels in ovarian cancer patients is significantly associated with poor survival (P = 0.016) unlike HERG channel expression where there was no correlation with survival. There was also a significant association of Eag staining with high tumour grade (P = 0.014) and presence of residual disease (P = 0.011). Proliferation of SK-OV-3 cells was significantly (P < 0.001) inhibited after treatment with voltage gated K+ channel blockers.ConclusionThis novel finding demonstrates a role for Eag as a prognostic marker for survival in patients with ovarian cancer.
Cancer Cell International | 2011
Viren Asher; Averil Y. Warren; Robert Shaw; Heidi M. Sowter; Anish Bali; Raheela Khan
BackgroundThe voltage gated potassium (K+) channels Eag and HERG have been implicated in the pathogenesis of various cancers, through association with cell cycle changes and programmed cell death. The role of these channels in the onset and progression of ovarian cancer is unknown. An understanding of mechanism by which Eag and HERG channels affect cell proliferation in ovarian cancer cells is required and therefore we investigated their role in cell proliferation and their effect on the cell cycle and apoptosis of ovarian cancer cells.MethodsThe presence of Eag and HERG was determined in SK-OV-3 cells using immunofluorescence and western blotting. The effect of the Eag blockers (imipramine and clofilium) and HERG blockers (E-4031 and ergtoxin) on cell proliferation was assessed using the MTS assay with further investigation of their role in the cell cycle and apoptosis determined by flow cytometry.ResultsEag and HERG channels were present in the cytoplasm and nuclei of SK-OV-3 cells. There was significant inhibition of proliferation of SK-OV-3 cells by imipramine (P < 0.001) and ergtoxin (P < 0.05) at 72 hours of culture. Incubation of cells with ergtoxin led to the accumulation of cells in the S and G2/M phase, while cells accumulated in S phase after incubation with E-4031, with no effect on apoptosis. Imipramine did not affect the cell cycle but increased the proportion of SK-OV-3 cells undergoing early apoptosis.ConclusionBoth Eag and HERG channels are expressed in SK-OV-3 ovarian cancer cells and have a role in cell proliferation. HERG channels affect the cell cycle while Eag channels are implicated in the inhibition of apoptosis of ovarian cancer cells. The family of Eag channels may represent a new therapeutic target for the treatment of ovarian cancer.
Journal of Medical Case Reports | 2011
Viren Asher; Gerhard van Schalkwyk; Anish Bali
IntroductionContrary to its name, synovial sarcoma does not arise from the synovial membrane but from multipotent stem cells and can present in any part of the body. Very few cases of vulval synovial sarcoma have been reported in the literature; we report on such a presentation. These tumors can present as painless lumps, which must be completely excised to give the best prognosis. Therefore the diagnosis of synovial sarcoma should always be kept in mind in the management of vulval masses, especially in young patients.Case presentationWe report the case of a 28-year-old Caucasian woman with synovial sarcoma of the vulva. Complete excision was possible in this case.ConclusionWe have presented a rare case of synovial sarcoma of the vulva, which can be easily confused with lipoma of the vulva. The management of this tumor requires referral to a cancer centre, with a multidisciplinary approach.
Medical Oncology | 2012
Viren Asher; Joanne Lee; Anish Bali
Anticancer Research | 2013
Anni Innamaa; Leigh Jackson; Viren Asher; Gerhard Van Shalkwyk; Averil Y. Warren; Daniel Hay; Anish Bali; Heidi M. Sowter; Raheela Khan
Clinical & Translational Oncology | 2013
Anni Innamaa; Leigh Jackson; Viren Asher; G. van Schalkwyk; Averil Y. Warren; A. Keightley; Daniel P. Hay; Anish Bali; Heidi M. Sowter; Raheela Khan
Perioperative medicine (London, England) | 2014
Stephanie Archer; Jane Montague; Anish Bali
Complementary Therapies in Medicine | 2015
Stephanie Archer; Elly Phillips; Jane Montague; Anish Bali; Heidi M. Sowter